Table 5. Details of patient and disease... | American Society of Hematology

Table 5.

Details of patient and disease characteristics and response to PEG IFN-α-2b

Patient no.	Age (y)	CML duration (mo)	PEG IFN-α-2b dose (μg/kg/wk)	Last IFN-α response	CML phase (active/CHR)	WBC pretreatment (× 10⁹/L)	Percent Ph⁺cells		Overall response on PEG IFN-α-2b
Patient no.	Age (y)	CML duration (mo)	PEG IFN-α-2b dose (μg/kg/wk)	Last IFN-α response	CML phase (active/CHR)	WBC pretreatment (× 10⁹/L)	Pre-PEG IFNα-2b	Lowest on therapy	Overall response on PEG IFN-α-2b
1^5-150	57	52	0.75	CHR	Second CP-A	15.6	100	NA	Resistant
2	23	97	0.75	PHR	Acc-A	25.4	100	NA	Resistant
3	60	43	0.75	PHR	CP-A	14.6	100	NA	Resistant
4	55	58	1.5	CHR	CP-A	13.3	100	100	CHR
5	21	12	1.5	PHR	Acc-A	21.8	100	NA	Resistant
6	55	137	1.5	Resistant	CP-A	38.6	100	100	CHR
7	46	36	3	CHR	CP-A	48.2	100	NA	Resistant
8	66	21	3	Resistant	CP-A	73.6	100	100	CHR
9^5-150	59	22	3	Minor CG	CP-A	18.2	100	0	Complete CG
10	40	38	4.5	CHR	CP-A	12.3	95	NA	Resistant
11	31	79	4.5	Resistant	CP-A	14.7	100	100	CHR
12	35	109	4.5	CHR	Acc-CHR	6.4	100	NA	Resistant
13	59	8	6	Partial CG	Acc-CHR	4.4	15	0	Complete CG
14^5-150	56	7	6	CHR	CP-A	11.9	100	0	Complete CG
15	34	99	6	Minor CG	CP-CHR	8.0	50	0	Complete CG
16	61	138	7.5	Resistant	Acc-A	53.2	100	100	Resistant
17^5-150	41	60	7.5	Minor CG	CP-CHR	7.9	50	0	Complete CG
18^5-150	33	78	7.5	CHR	CP-A	9.3	100	NA	Resistant
19	47	50	7.5	CHR	Acc-A	19.0	100	100	PHR
20^5-150	50	25	7.5	Partial CG	CP-CHR	4.6	30	5	Partial CG
21	50	144	7.5	PHR	CP-A	52.0	100	100	CHR
22	45	45	9	CHR	Acc-A	13.6	100	100	PHR
23	33	90	9	Partial CG	CP-CHR	6.5	20	0	Complete CG
24	41	106	9	CHR	CP-A	10.5	100	100	PHR
25	47	30	9	Minor CG	Acc-CHR	5.4	69	17	Partial CG
26^5-151	56	50	9	PHR	Acc-A^5-151	71.1	100	100	Second CP
27	54	14	9	Minor CG	CP-CHR	7.2	75	25	Partial CG

Patient no.	Age (y)	CML duration (mo)	PEG IFN-α-2b dose (μg/kg/wk)	Last IFN-α response	CML phase (active/CHR)	WBC pretreatment (× 10⁹/L)	Percent Ph⁺cells		Overall response on PEG IFN-α-2b
Patient no.	Age (y)	CML duration (mo)	PEG IFN-α-2b dose (μg/kg/wk)	Last IFN-α response	CML phase (active/CHR)	WBC pretreatment (× 10⁹/L)	Pre-PEG IFNα-2b	Lowest on therapy	Overall response on PEG IFN-α-2b
1^5-150	57	52	0.75	CHR	Second CP-A	15.6	100	NA	Resistant
2	23	97	0.75	PHR	Acc-A	25.4	100	NA	Resistant
3	60	43	0.75	PHR	CP-A	14.6	100	NA	Resistant
4	55	58	1.5	CHR	CP-A	13.3	100	100	CHR
5	21	12	1.5	PHR	Acc-A	21.8	100	NA	Resistant
6	55	137	1.5	Resistant	CP-A	38.6	100	100	CHR
7	46	36	3	CHR	CP-A	48.2	100	NA	Resistant
8	66	21	3	Resistant	CP-A	73.6	100	100	CHR
9^5-150	59	22	3	Minor CG	CP-A	18.2	100	0	Complete CG
10	40	38	4.5	CHR	CP-A	12.3	95	NA	Resistant
11	31	79	4.5	Resistant	CP-A	14.7	100	100	CHR
12	35	109	4.5	CHR	Acc-CHR	6.4	100	NA	Resistant
13	59	8	6	Partial CG	Acc-CHR	4.4	15	0	Complete CG
14^5-150	56	7	6	CHR	CP-A	11.9	100	0	Complete CG
15	34	99	6	Minor CG	CP-CHR	8.0	50	0	Complete CG
16	61	138	7.5	Resistant	Acc-A	53.2	100	100	Resistant
17^5-150	41	60	7.5	Minor CG	CP-CHR	7.9	50	0	Complete CG
18^5-150	33	78	7.5	CHR	CP-A	9.3	100	NA	Resistant
19	47	50	7.5	CHR	Acc-A	19.0	100	100	PHR
20^5-150	50	25	7.5	Partial CG	CP-CHR	4.6	30	5	Partial CG
21	50	144	7.5	PHR	CP-A	52.0	100	100	CHR
22	45	45	9	CHR	Acc-A	13.6	100	100	PHR
23	33	90	9	Partial CG	CP-CHR	6.5	20	0	Complete CG
24	41	106	9	CHR	CP-A	10.5	100	100	PHR
25	47	30	9	Minor CG	Acc-CHR	5.4	69	17	Partial CG
26^5-151	56	50	9	PHR	Acc-A^5-151	71.1	100	100	Second CP
27	54	14	9	Minor CG	CP-CHR	7.2	75	25	Partial CG

CP indicates chronic phase; Acc, accelerated phase; NA, not applicable; A, active disease; CG, cytogenetic; Minor CG, Ph 35%-90%; partial CG, Ph 1%-34%; complete CG, Ph 0%.

F5-150

Entered for IFN-α intolerance.

F5-151

Accelerated blasts ≥ 15%.

View Large